Apellis Pharmaceuticals (APLS) is planning to raise $150 million in an IPO on Thursday, November 9th, IPO Scoop reports. The company will issue 10,700,000 shares at a price of $13.00-$15.00 per share.
Apellis Pharmaceuticals has a market-cap of $689.6 million.
Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.
Apellis Pharmaceuticals provided the following description of their company for its IPO: “We are a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases. “.
Apellis Pharmaceuticals was founded in 2009 and has 28 employees. The company is located at 6400 Westwind Way, Suite A, Crestwood, KY 40014, US and can be reached via phone at (502) 241-4114 or on the web at http://www.apellis.com.
What are top analysts saying about Apellis Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Apellis Pharmaceuticals and related companies.